Headquartered in New York, NY·Fiscal year ends December·NYSE: PFE·pfizer.com
About Pfizer
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes medicines and vaccines worldwide.
**Business structure**
Nearly all revenue comes from its Global Biopharmaceuticals Business (Biopharma). Biopharma operates through three divisions:
- Pfizer U.S. Commercial Division
- Pfizer International Commercial Division
- Global Hospital and Biosimilars Division
**Product portfolios**
- **Primary Care:** Eliquis, the Prevnar family, Nurtec ODT/Vydura, Comirnaty, Abrysvo, Paxlovid and FSME-IMMUN/TicoVac.
- **Oncology:** Ibrance, Padcev, Xtandi, Lorbrena, Inlyta, Braftovi/Mektovi, Adcetris, Orgovyx, Tukysa, Bosulif, Elrexfio, Talzenna and Tivdak.
- **Specialty Care:** the Vyndaqel family, Xeljanz, Zavicefta, Enbrel, Octagam, BeneFIX, Cresemba, Genotropin and Cibinqo.
- **Hospital and Biosimilars (formed in 2026):** off-patent sterile injectables and biosimilars such as Retacrit, Ruxience, Zirabev, Inflectra and Sulperazon.
**Other operations and revenue sources**
- Pfizer CentreOne provides contract manufacturing and active pharmaceutical ingredient sales.
- Revenue comes from product sales, alliance revenues (e.g., Eliquis, Xtandi, Orgovyx) and royalties.
- The U.S. accounts for roughly two-thirds of sales.
**Strategy**
Pfizer is shifting away from declining COVID-19 products toward launched and acquired medicines, including those from the Seagen acquisition. It is investing in oncology, obesity, immunology and next-generation vaccine programs. It is also executing an enterprise-wide cost realignment and de-levering its balance sheet. Updated
Revenue by Segment · Q3 2026
Global Biopharmaceuticals Business98%
Pfizer CentreOne2%
Latest Activity
PodcastMad Money w/ Jim CramerJim Cramer · 44 min
Mad Money: Wall Street Jargon, Cyclicals, GARP & Corrections 11/13/26
Cramer defines cyclicals as economy-dependent: miners like BHP, autos, homebuilders, commodity chemicals
Secular growers are the recession-proof side: Procter & Gamble, General Mills, Pfizer, Merck, Eli Lilly
He flags GLP-1 drugs as the one threat to the eat-and-drink-forever staples thesis
Caller advice: 70% stocks even for older investors, and ease idle IRA cash in one-twelfth a month
The practical call is positioning: own more cyclicals when business is booming and lean on staples and drugmakers when growth rolls over. Cramer says sector membership now drives well over half of a stock's move thanks to sector ETFs, so being in the wrong camp costs you even when the company executes.
Pfizer is outrunning its COVID hangover: Paxlovid sales fell 63%, yet full-year revenue guidance rose to $62 billion to $64 billion. That is the seventh straight quarter of topping EPS expectations.
New 52-week high$30.52+0.3% vs prior high · 2026-10-22
Pfizer cleared $30 for the first time in a year, closing at $30.52 and topping its October 22 peak by 0.33%. The $173.9 billion drugmaker was trading near $23 twelve months ago.
New 52-week high$29.21+0.7% vs prior high · 2026-09-02
Pfizer hit a fresh 52-week high at $29.21, topping its September 2 peak. The drugmaker is now trading at levels no buyer from the past year is underwater on.
A stock-only portfolio paying over $12,000 a month sounds like a retirement dream, but the income splits into layers with very different levels of reliability. Before you build it, you need to…
Three popular high-yield stocks promise a steady retirement paycheck, but one has a thin cash cushion and another has slashed its payout before. Which one could quietly shrink your monthly income when…
Pfizer (NYSE:PFE | PFE Price Prediction) closed at $28.83 on Nov. 12, 2026, up 15.78% from its $24.90 close on Dec. 31, 2025. A $1,000 purchase at the Nov. 30, 2021 month-end…
A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they…
Pfizer just convinced Wall Street's biggest private investor to shoulder its obesity bet, yet the payoff for shareholders may not come from the drug at all. The real story sits in who…
Pharmacy counters stay busy in every kind of market. Blood thinners, cancer drugs, and vaccines get refilled on schedule, and the companies that make them return part of those sales to shareholders…
A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know…
A pre-tax 401(k) hides a tax bill nobody has paid yet, and the way you settle it can swing the cost by six figures. One timing choice, plus a December 31 deadline,…
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.…
Drugs, software, cereal, and electricity keep selling when the economy stalls. Five dividend payers pass a coverage test, but one carries a payout stretched thin and another faces a regulatory hearing that…
Pre-Market Stock Futures: Futures are mixed this Friday morning, with the Dow Jones trading lower, but Nasdaq futures are higher as AI stocks catch a bid after the big post-election rally…
When a heavily indebted company has to refinance at higher rates, every extra dollar of interest comes out of the same cash pool that funds the dividend. Bondholders have a legal claim…
Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.52, up 5% in afternoon trading, as the…
Six high-yield stocks, one portfolio, and two very different tax bills waiting at the end of each year. Where you hold these positions matters far more than most investors realize before they…
Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything. Whether the…
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes medicines and vaccines worldwide. **Business structure** Nearly all revenue comes from its Global Biopharmaceuticals Business (Biopharma). Biopharma operates through three divisions: - Pfizer U.S.
What is the PFE stock price target?
24/7 Wall St.'s 12-month price target for PFE is $34.62, rated Buy. The Wall Street consensus target is $30.22. PFE price prediction →